Hemlibra gets priority review

Roche (SIX:ROG; OTCQX:RHHBY) said FDA accepted and granted Priority Review to its sBLA for Hemlibra

Read the full 159 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE